[source from:Global Business Reports ] Can you introduce HighTide Therapeutics and present key highlights from 2022? HighTide was founded in 2011. We are a globally integrated biotech company with operations in the US and China.

[ source from:Biopharma ] HighTide Therapeutics Inc. a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phas

[ source from：the Washington Business Journal ] Metabolic and digestive disease specialist HighTide Therapeutics has raised $107 million in a series C financing led by China’s TCM Healthcare Fund, with money also from Yuexiu Fund and Yuthai Fund.

[ source from：The pharma letter ] Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.

[ source from：Endpoints News ] HighTide Therapeutics has raised a $107 million Series C round to fund mid-stage studies in metabolic and digestive diseases, with the goal of filing for approval in China within two to three years.